The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload

A L Sverdlov, D T M Ngo, A K Nightingale, S Rajendran, K Mishra, T Heresztyn, R H Ritchie, T H Marwick, M P Frenneaux, J D Horowitz

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Nitric oxide (NO) is a modulator of left ventricular hypertrophy (LVH) and myocardial relaxation. The impact of NO availability on development of LVH has never been demonstrated in humans. We tested the hypotheses that elevation of asymmetric dimethylarginine (ADMA) concentrations (biochemical marker of decreased NO generation), and impairment of vascular responsiveness to NO donor GTN, would each predict the presence of LVH and associated LV diastolic dysfunction in a normal aging population.
Original languageEnglish
Pages (from-to)41-46
Number of pages6
JournalNitric Oxide: Biology and Chemistry
Volume25
Issue number1
DOIs
Publication statusPublished - 30 Jun 2011

Keywords

  • left ventricular mass
  • nitric oxide
  • vascular function
  • diastolic function
  • asymmetric dimethylarginine

Fingerprint Dive into the research topics of 'The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload'. Together they form a unique fingerprint.

  • Cite this

    Sverdlov, A. L., Ngo, D. T. M., Nightingale, A. K., Rajendran, S., Mishra, K., Heresztyn, T., Ritchie, R. H., Marwick, T. H., Frenneaux, M. P., & Horowitz, J. D. (2011). The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. Nitric Oxide: Biology and Chemistry, 25(1), 41-46. https://doi.org/10.1016/j.niox.2011.04.009